Richard Lafayette, MD, FACP

home / authors / richard-lafayette-md-facp

Richard Lafayette, MD, FACP, is professor of medicine, nephrology, and director, Glomerular Disease Center, Stanford University Medical Center, and Vanrafia ALIGN study investigator and steering committee member.

Articles

June 24th 2025

Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP

Maggie L. Shaw Richard Lafayette, MD, FACP

Richard Lafayette, MD, FACP, explains why a REMS program is not required for the endothelin A receptor antagonist and how patients may need to adjust should final ALIGN trial data fail to show a clinical benefit of atrasentan.

Richard Lafayette, MD, FACP, Stanford University Medical Center

April 11th 2025

New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP

Maggie L. Shaw Richard Lafayette, MD, FACP

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.